With the steadily increasing occurrence of antibiotic resistance in bacteria, there is a great need for new antibacterial compounds. The approach described here involves targeting virulencerelated bacterial type IV secretion systems (TFSSs) with small-molecule inhibitors. The cag TFSS of Helicobacter pylori was chosen as a model, and novel inhibitors directed against the cag VirB11-type ATPase Caga were identified. The cag genes encode proteins that are components of a contact-dependent secretion system used by the bacterium to translocate the effector molecule CagA into host cells. Translocated CagA is associated with severe gastritis, and carcinoma. Furthermore, functional TFSSs and immunodominant CagA play a role in interleukin (IL)-8 induction, which is an important factor for chronic inflammation. Inhibitors of Caga were identified by highthroughput screening of chemical libraries that comprised 524 400 small molecules. The ATPase activity of Caga was inhibited by the selected compounds in an in vitro enzymic assay using the purified enzyme. The most active compound, CHIR-1, reduced TFSS function to an extent that cellular effects on AGS cells mediated by CagA were virtually undetectable, while reduced levels of IL-8 induction were observed. Gastric colonization by CHIR-1-pre-treated bacteria was found to be impaired in a dose-dependent manner using a mouse model of infection. Small-molecule Caga inhibitors, the first described inhibitors of a TFSS, are potential candidates for the development of new antibacterial compounds that may lead to alternative medical treatments. The compounds are expected to impose weak selective pressure, since they target virulence functions. Moreover, the targeted virulence protein is conserved in a variety of bacterial pathogens. Additionally, TFSS inhibitors are potent tools to study the biology of TFSSs.
INTRODUCTION
Widespread emergence of bacterial pathogens that are resistant to common antibiotics calls for innovative antibacterial drugs. Targeting virulence functions, instead of enzymic activities that are essential in vitro, is a new approach and may represent a way to reduce the rate of resistance formation. Virulence genes often encode functions involved in host-pathogen relationships, such as persistence and invasion, and therefore they are non-essential under laboratory conditions, but they are required for successful propagation of a pathogen within the host. Hence, the resulting selective pressure that could give rise to resistance is expected to be weaker than for housekeeping genes.
Type IV secretion systems (TFSSs) have been recognized as major virulence determinants in bacteria that are pathogenic to animals and plants (Agrobacterium, Brucella, Bartonella, Bordetella, Helicobacter, Legionella, Rickettsia and Wolbachia). TFSSs are required for delivery of effector molecules, either directly into host cells or to the bacterial environment (Ding et al., 2003; Christie et al., 2005; Bourzac & Guillemin, 2005) .
We have chosen the well-studied human gastroduodenal pathogen Helicobacter pylori as a model system to demonstrate that virulence functions encoded by TFSSs can be targeted for use in antibacterial therapy. While it is estimated that about half of the world population is infected Abbreviations: ATPase, adenosine triphosphate hydrolase; HTS, highthroughput screening; IL, interleukin; NTPase, nucleoside triphosphate hydrolase; PAI, pathogenicity island; TFSS, type IV secretion system. with H. pylori (Rothenbacher & Brenner, 2003) , it has been recognized that severe outcomes of the infection, e.g. acute gastritis, peptic ulceration, formation of MALT lymphoma and adenocarcinoma, are associated with the presence of the cag pathogenicity island (PAI) (Bourzac & Guillemin, 2005; Censini et al., 1996) in the H. pylori chromosome. The presence of the cag PAI has been linked to virulent type I strains, whereas strains lacking the PAI are less virulent, and classified as type II strains (Censini et al., 1996) . The cag PAI encodes protein components of a TFSS that has been shown to play a major role in H. pylori virulence (Covacci et al., 1997; Censini et al., 1996) . To date, the only known effector molecule that has been identified to be secreted by cag is the CagA protein (Stein et al., 2002 (Stein et al., , 2000 Backert et al., 2000; Odenbreit et al., 2000) .
CagA is targeted to epithelial cells, where it is tyrosine phosphorylated at EPIYA sites by c-Src and Lyn host kinases (Stein et al., 2002) . Phosphorylated CagA triggers a signal cascade that promotes cell motility and proliferation, and leads to the characteristic 'hummingbird' phenotype (Segal et al., 1999) , involving formation of lamellipodia and filopodia. Another CagA-mediated effect results from the fact that translocated CagA localizes to the cell membrane, and promotes redistribution of the proteins ZO-1 and JAM, which are normally found at tight cell junctions (Amieva et al., 2003) . This redistribution occurs independently of the phosphorylation state of CagA phosphorylation state and leads to leakiness of the junctions (Amieva et al., 2003) .
The presence of a functional cag TFSS results in NF-kB activation in infected gastric epithelial cells, and leads to pro-inflammatory responses, such as IL-8 release (Crabtree et al., 1995) . Although the mechanism by which a functional cag TFSS induces pro-inflammatory responses is still not fully understood, there are two candidate mechanisms, both of which may contribute to the observed effects: (i) the presence of cag facilitates entry of peptidoglycan fragments into host cells, and these are sensed by the intracellular receptor Nod1, resulting in NF-kB activation (Viala et al., 2004) ; and (ii) CagA itself seems to be capable of potentiating pro-inflammatory responses, as shown by gene replacement and mutagenesis studies (Brandt et al., 2005 ).
The cag TFSS of H. pylori encodes several proteins that show significant similarity with gene products of the paradigmatic vir TFSS of the Agrobacterium tumefaciens T-DNA transfer system (Akopyants et al., 1998; Christie & Vogel, 2000; Christie, 2001; Christie et al., 2005) . The vir TFSS is formed by 12 proteins (VirB1-11, plus the coupling protein VirD4) (Christie, 2001) .
The assembly process is not yet defined at the molecular level, but mutations within the virB operon have resulted in lack of polymerization, and absence of functions. Mutants of VirB4, VirB7, VirB9, VirB10 and VirB11 all show functional impairment, and lack polymerization of the conduit used for delivery of the effectors (Fernandez et al., 1996; Berger & Christie, 1994) .
Three proteins that contain NTP-binding motifs have been identified: the prototypes are VirB4, VirB11 and VirD4. To date, in vitro NTPase activity has been shown for the VirB11-type proteins (Krause et al., 2000b; Machon et al., 2002) and for one member of the VirD4 family, TrwB (Tato et al., 2005) . For several VirB11-type proteins, a ring-like hexameric structure has been demonstrated (Krause et al., 2000a) , and this has been confirmed by X-ray structural analysis of the H. pylori Caga NTPase (Yeo & Waksman, 2004; Yeo et al., 2000) .
Although VirB11-type NTPases have been very well characterized structurally (Krause et al., 2000a; Savvides et al., 2003; Yeo et al., 2000) and biochemically (Krause et al., 2000b; Machon et al., 2002; Rivas et al., 1997) , their function in TFSSs remains unclear. Members of this class of enzymes are also present in the type II secretion systems, and type 4 pilus systems (Planet et al., 2001; Krause et al., 2000a; Rivas et al., 1997) , and a role in the formation of the pilus-like cell appendages, which are commonly associated with TFSS, has been suggested (Sagulenko et al., 2001 ). VirB11-type proteins are essential for TFSS function, as shown by mutagenesis studies (Berger & Christie, 1994) , and their NTPase activity is detectable in vitro using purified protein, without the requirement of complex cofactors (Krause et al., 2000b; Rivas et al., 1997) ; these two properties make VirB11-type proteins, such as H. pylori Caga, ideal targets for use in high-throughput screening (HTS) to search for compounds that specifically inhibit TFSS function.
Here, we describe the identification and validation of three specific inhibitors of Caga, which is the VirB11 homologue of cag. The compounds efficiently inhibit Caga ATPase activity in vitro. We demonstrate that one of the compounds reduces cag activity to the limits of detection, as measured by transfer of CagA protein from H. pylori to eukaryotic host cells. In a mouse model of infection, bacteria that had been pre-treated with the inhibitor showed impaired ability to colonize the gastric mucosa. Implications for application of TFSS inhibitors as a new type of anti-infective, representing the first described inhibitor of a TFSS, as well as a new tool for studying the mechanism of action of TFSSs, are discussed.
METHODS
Bacterial strains, cell lines and culture conditions. H. pylori strains G27 and SPM 326, and mutants G27DHP527 (cagY) and G27DcagA, have been described (Marchetti et al., 1995) . Strains were cultivated on Columbia agar base (Oxoid) containing 5 % (v/v) defibrinated horse blood or 5 % (v/v) fetal bovine serum (FBS), and Dent's antibiotic supplement (Oxoid). BHI and Brucella broth (BB) media were supplemented with 5 % FBS and appropriate antibiotics. Bacitracin (Sigma-Aldrich) was used at a concentration of 200 mg ml 21 . Bacteria were incubated at 37 uC, under microaerophilic conditions. AGS cells (European Collection of Cell Cultures no. 89090402) were grown at 37 uC in 5 % CO 2 /95 % air in Dulbecco's modified Eagle's medium (DMEM), with 10 % (v/v) FBS and 1?5 mM L-glutamine.
Caga in vitro assay. Native Caga protein (HP0525) was obtained from induced Escherichia coli SCS1 (pWP4525) cells, as described previously (Krause et al., 2000b) . The ATPase activity of Caga was assessed using a chromogenic reagent based on the classical malachite green reagent for detection of P i (BIOMOL Green reagent). Briefly, Caga (approx. 0?4 mg in a total reaction volume of 40 ml) was incubated for 45 min at 37 uC in reaction buffer (20 mM Tris/ HCl, pH 8?0, 50 mM NaCl, 2?5 mM MgCl 2 , 0?1 mM EDTA, and 0?05 % Brij-35) in the presence of 1 mM ATP. Following the incubation period, 60 ml reaction buffer was added, followed by 1 ml BIOMOL Green reagent. The concentration of P i was determined by measuring the absorbance at 620 nm, after an incubation period of 30 min at 25 uC.
Chemical library. The compound collection belonged to the Chiron Corporation (Emeryville) substance libraries. For HTS, 524 400 diverse chemicals were selected, all of which were small molecules (M r <600), and of diverse structure. Five hundred thousand of the compounds were derived from Chiron's combined chemical libraries (CombiChem). We did not use a focused library, such as one containing analogues of ATP or ADP.
Assay methodology for Caga inhibitors (HTS). Test compounds were added to DMSO at 406 final concentration, and dispensed into 384-well polypropylene plates (1 ml per well). Using a Multidrop dispenser (Thermo), 20 ml buffer/salt solution (20 mM Tris, pH 8?0, 50 mM NaCl, 5 mM MgCl 2 , and 200 mM ATP; Roche Applied Sciences) was added to each well, and the plates were shaken briefly to mix in the compounds. The Caga enzyme (HP0525) was diluted to 2?25 mg ml 21 in a buffer/salt solution consisting of 20 mM Tris, pH 8?0, 50 mM NaCl, and 0?1 % Brij-35. Again using the Multidrop dispenser, 20 ml of the enzyme solution was added to the plates to start the reaction. The plates were incubated at 37 uC for 45 min, at which time the reaction was terminated, and detection of free phosphate was initiated by the addition of 60 ml Green reagent. After 30 min at room temperature, the plates were stacked, ten at a time, onto two Victor 2 plate readers (Perkin Elmer), and absorbance at 625 nm was measured. Two readers were used for each set of 20 plates, so that all were read within 1 h of the addition of Green reagent. Data were analysed using ActivityBase software (IDBS).
Hit evaluation (re-screening of hit candidates). Evaluation of hits was performed by re-screening the compounds in a doseresponse assay. The most potent compounds were analysed by LC/ MS to determine purity, and to confirm the intended structure. For further study, selected compounds were repurified by HPLC and reassayed to calculate their IC 50 values. Some compounds were contaminated with heavy metals; therefore, 0?1 mM EDTA was included in follow-up assays to avoid inhibition of Caga activity by heavy metal ions. Inhibitory activity was crosschecked against non-VirB11-type ATPases, e.g. E. coli RecA protein (Sigma-Aldrich) in the presence of ssDNA, and canine Na
Inhibitor studies. H. pylori Caga inhibitor CHIR-1 was used at concentrations of 0-25 mM (100 mM stock solution in DMSO) for the in vitro enzymic assay. For cell culture experiments with AGS cells, 25, 50 and 75 mM solutions of CHIR-1 were applied. All controls were performed with the respective amount of DMSO. Preceding the infection protocol, overnight cultures of H. pylori or AGS cells were pre-incubated with CHIR-1 at 37 uC for up to 30 min; otherwise, the bacteria were added to the monolayer simultaneously with the supplemented medium. Cell viability was tested using the cell proliferation reagent WST-1 (Roche), according to the manufacturer's instructions. ), and a membrane fraction, was performed as described by Stein et al. (2000) .
Antibodies and immunoprecipitation. Immunoprecipitation with anti-phosphotyrosine (PY99; Santa Cruz Biotechnology) was carried out according to the protocols provided by the supplier. Anti-tubulin antibody (T-9026) was obtained from Sigma. Antibodies against G27 CagA (rabbit) and G27 urease (rabbit) were produced in our laboratory (F. Bagnoli, L. Buti, S. Censini, W. Pansegrau, I. Russo & M. Stein, unpublished results; Stein et al., 2000) . Secondary antibodies were obtained from Bio-Rad.
Assay for IL-8 induction by epithelial cells. AGS cells were cultivated in 75 ml tissue-culture flasks in a medium containing DMEM supplemented with L-glutamine and 5 % FBS. Cells were harvested by trypsinization, and resuspended in supplemented DMEM to a concentration of 2610 5 cells ml 21 . A 2 ml volume of the cell suspension was added to each well of a six-well plastic tissue-culture plate, and incubated until the monolayer was confluent to about 80 %. A H. pylori G27 culture grown overnight was harvested in PBS, and resuspended to a density of approximately 10 8 c.f.u. ml 21 . Dilutions of 1 : 3 and 1 : 10 were prepared. Where indicated, bacteria were pre-incubated with DMEM/CHIR-1 at 37 uC, before adding 1?5 ml of the suspension to the monolayer. Otherwise, bacteria were added simultaneously with the respective medium to the AGS cells. After 4 and 24 h microaerophilic incubation, samples (500 ml) were taken and centrifuged (15 000 g), before freezing at 280 uC, until assayed. The volume removed was replaced by fresh DMEM/CHIR-1, and phenotypic changes of AGS cells were estimated by light microscopy. Additionally, 20 ml samples were removed and incubated under microaerophilic conditions in 1 ml BB medium for up to 5 days to control the viability of H. pylori G27.
Cytokine assay. The level of IL-8 in cell culture supernatants was determined by use of a commercially available human IL-8 ELISA kit (OptEIA; BD Biosciences), and expressed in pg ml 21 .
Confocal immunofluorescence. Infected AGS monolayers on glass coverslips were fixed with 3 % formaldehyde in PBS, with 1 mM CaCl 2 and 1 mM MgCl 2 . Following permeabilization with 0?2 % Triton X-100, anti-H. pylori antibodies (a-CagA, rabbit) were applied to the coverslips. Green Alexa Fluor 488 goat anti-rabbit IgG (A-11034; Molecular Probes) was used as a secondary antibody.
Mouse colonization assays. Specific-pathogen-free CD1 mice (Charles River Laboratories) were housed and treated in compliance with current Italian law. After a 16-h starvation period, 6-week-old CD1 mice (10 animals per group) were infected, as previously reported (Marchetti et al., 1995) , with minor modifications. Immediately before challenge, bacteria were harvested from plates by a sterile cotton swab, resuspended in supplemented BHI medium, and their concentration was determined spectrophotometrically. An OD 535 of 1 in a cuvette with a 1 cm path length corresponds to 10 9 c.f.u. ml 21 . H. pylori exists as an actively dividing, highly motile, spiral form, and a non-culturable, but viable, metabolizing coccoid form. Others (Cole et al., 1997) have shown that the coccoid form of H. pylori, in contrast to the spiral form, binds poorly to gastric epithelial cells. Therefore, the phenotype of bacterial cultures, i.e. motility and spiral shape, was monitored microscopically so that we were able to initiate infection experiments with motile spiral cells. Mice were given 0?25 ml of 0?2 M NaHCO 3 , intragastrically, to neutralize acidity, about 15 min before challenge. Through the same route, either 10 9 (high dose of H. pylori) or 10 8 (standard dose of H. pylori) c.f.u. in 100 ml saline was delivered directly into the stomach of each mouse. Where indicated, bacteria were pre-treated with 25 or 50 mM CHIR-1 in DMSO (3?5 and 7 mM, respectively) for approximately 30 min before challenge (controls received 7 mM DMSO). The number of c.f.u. in inocula was determined by subsequent plate culture. Groups that received the standard infecting dose of H. pylori were further infected with the same bacterial dose 2 days later; infection was not repeated in mice that received the high dose. Forty-eight hours after each infection, a second dose of inhibitor (in 150 mM NaCl) was administered. Four and eleven days after infection with high and low dose, respectively, the animals were euthanized by carbon dioxide asphyxiation and their stomachs were removed immediately. Gastric mucosa was scraped from the stomach of each mouse, and, after serial dilution, this was spread on selective plates, which had been prepared as described above, with addition of 0?2 mg bacitracin ml 21 . H. pylori c.f.u. were counted after 6 days.
Statistical analysis. The statistical significance of the data was evaluated by a one-tailed Mann-Whitney U test or Fisher's exact test. For all comparisons, probability values less than 5 % (P<0?05) were considered statistically significant.
RESULTS

HTS of Caga identifies three potent small-molecule inhibitors
The ATPase activity of Caga was measured by assessing the P i liberated during the Caga in vitro assay. Quantification of free phosphate was performed by measuring absorbance at 620 nm using BIOMOL Green reagent. The laboratory-scale enzymic assay was adapted to HTS in 384-well plates (see Methods). A chemical library of 524 400 compounds was screened to identify inhibitors of Caga ATPase activity. CombiChem compounds were tested in pools, at a final concentration of 1 mM for each substance; other compounds were added at a final concentration of 5 mM to the assay mixture, either as single compounds or as mixtures of five compounds. In an initial screen, 675 compounds were found to inhibit Caga ATPase activity by at least 50 %. Rescreening and verification of primary hits was performed in dose-response assays, resulting in 200 confirmed hits that had preliminary IC 50 values of less than 10 mM. After deconvolution of any pooled compound hits, 33 single compounds, thereof, showed IC 50 values of 5 mM or less, and 20 showed values of 1 mM or less. Structural considerations to exclude undesirable structures with reactive groups, or structures difficult to modify, led to a selection of seven compounds. These compounds were analysed by LC/MS for purity, and to confirm their intended structure, followed by further studies after repurification by HPLC. The seven compounds considered for more comprehensive evaluation had not been identified as significant kinase inhibitors in other screens, nor had they shown inhibitory activity in other HTS assays.
Three of the seven compounds (CHIR-1, -2 and -3) retained IC 50 values of <1 mM (Table 1) in further screens. Remarkably, two compounds, CHIR-1 and CHIR-2, were structurally closely related, falling into the class of thiadiazolidine-3,5-diones. The compound with the lowest IC 50 value, CHIR-1, was acquired in larger amounts to confirm the inhibition properties of the substance, and to perform the experiments described below. Crosschecking its in vitro activity against non-VirB11-type ATPases [a mammalian ATPase (canine Na + /K + -ATPase), and bacterial RecA protein] revealed 10-and 5-fold higher IC 50 values, respectively (data not shown).
CHIR-1 suppresses the hummingbird phenotype in infected AGS cells
Infection of gastric cell lines by type I strains of H. pylori induces the so-called hummingbird phenotype, characterized by lamellipodia and filopodia, with spreading and elongated growth of the cells (Segal et al., 1999) . We investigated the effect of CHIR-1 on H. pylori in an infection experiment in which the translocation of CagA, and the resulting hummingbird phenotype, were indicators of the functionality of the H. pylori TFSS.
AGS cells (Fig. 1a) were infected with the wild-type strain G27, or with G27DcagA as a negative control. To study the influence of CHIR-1, AGS cells were co-cultivated with the wild-type strain pre-incubated in the presence of CHIR-1. Wild-type H. pylori G27 induced cytoskeletal rearrangement, resulting in the hummingbird phenotype (Fig. 1b) , whereas the DcagA mutant of G27 did not (Fig. 1c) . Following pre-incubation of H. pylori for 30 min in the presence of 50 mM CHIR-1, and co-cultivation with AGS cells in the presence of 50 mM CHIR-1 for 4 h, a reduction in the number of cells showing the hummingbird phenotype, which was comparable with that for the DcagA mutant, was observed (Fig. 1e) . A similar reduction of the hummingbird phenotype was not observed with bacterial cells that had not been pre-incubated with CHIR-1 (Fig. 1d) .
The MIC value of CHIR-1 with H. pylori G27 was calculated to be 90 mM, as determined by serial dilution of the inhibitor in a bacterial suspension. Human AGS cell toxicity of CHIR-1 was tested using a colorimetric assay, based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases. AGS cell viability was not affected by CHIR-1 concentrations up to 100 mM (data not shown). The effect of CHIR-1 on CagA translocation was studied by confocal fluorescence microscopy ( Fig. 2) . AGS cells were infected with wild-type H. pylori, and CagA protein was visualized in permeabilized cells using a polyclonal antiCagA antibody. A secondary antibody conjugated with Green Alexa Fluor 488 was used for CagA detection. AGS cells (60 % confluent) were infected with 10 7 c.f.u wild-type H. pylori in 12-well culture plates. In the untreated controls, the signal intensity of CagA within the bacterial cells was relatively low, while in the AGS cells, a faint and diffuse fluorescence signal, due to CagA translocation, was observed ( Fig. 2a-c) . However, upon co-cultivation of AGS cells with H. pylori cells that had been pre-cultivated in the presence of 50 mM CHIR-1, CagA was visible virtually exclusively within the bacterial bodies, in which the protein accumulated in significant amounts (Fig. 2d-f) .
As demonstrated by fluorescence intensity, at least a threefold higher concentration of CagA was demonstrated in H. pylori cells in AGS-H.-pylori co-cultivates that were treated with CHIR-1, compared with untreated co-cultivates (Fig. 2g) . Correspondingly, as compared with the untreated control, a similar (three-to fourfold) decrease in mean fluorescence intensity was observed in AGS cells in AGS-H.-pylori co-cultivates treated with CHIR-1 (Fig. 2g ). These findings demonstrate that translocation of CagA is much reduced by the action of CHIR-1. The effect was comparable with that seen with H. pylori cag mutants defective in Caga (VirB11) (Backert et al., 2000) .
CagA translocation into AGS cells is blocked by CHIR-1
To quantify the inhibitory effect of CHIR-1 on CagA translocation more precisely, we took advantage of the fact that CagA becomes tyrosine phosphorylated in the host cell. Therefore, the amount of tyrosine-phosphorylated CagA (pCagA) can be used as a readout for CagA translocation. Following co-cultivation of AGS cells with H. pylori G27, infected cells were harvested together with the attached bacteria, and a total extract was prepared. Phosphorylated proteins were enriched by immunoprecipitation from the total cell extract using anti-phosphotyrosine antibodies. Phosphorylated CagA (pCagA) protein was detected in the precipitate of untreated cells by Western blot analysis (Fig. 3, lanes 2 and 3) . Again, 50 mM CHIR-1 was sufficient to inhibit CagA translocation into AGS cells to the limits of detection for our study (Fig. 3, lanes 6 and 7) . Once more, a short period of pre-incubation of H. pylori cells in the presence of the inhibitor was necessary to achieve complete inhibition of CagA transfer. Without pre-incubation, a detectable amount of CagA reached the recipient cells (Fig. 3, lanes 4 and 5) . Importantly, the total amount of CagA remained constant, indicating that the different quantities of pCagA measured were not due to variable overall amounts of CagA resulting from CHIR-1 treatment (Fig. 3, lower panel) . Intracellular concentrations of H. pylori a-urease and AGS a-tubulin were not altered during a 4 h incubation period in the presence of 50 mM CHIR-1, when compared with a control without CHIR-1 (data not shown).
To determine the minimum period of time required for preincubation, and to compare it with the time required for CagA transfer, H. pylori G27 cells were exposed to CHIR-1.
Aliquots of the treated H. pylori cells were applied in co-cultivation experiments with AGS cells, in the presence of CHIR-1, and the amount of phosphorylated CagA (pCagA) was determined as described above (Fig. 3) . CagA transfer activity was reduced significantly between 1 and 3 min of pre-incubation (Fig. 4, bars 6 and 7) . The incubation period required for this effect to occur was short (<3 min) compared with the time required for CagA transfer, which was in the range of 30 min. The finding that a significant quantity of CagA reaches the AGS cells in the presence of CHIR-1, without the pre-incubation step, suggests that the inhibitor is effective only for a short time period at the beginning of the secretion process, and that transfer of CagA then becomes resistant to the action of CHIR-1. This might be related to the observation that contact establishment between AGS cells and H. pylori is a fast process that requires less than 5 min (F. Bagnoli, personal communication). Pre-incubation of the AGS cells with the inhibitor had no effect on CagA transfer (Fig. 4, bar 2) . (Fischer et al., 2001; Selbach et al., 2002) , and is influenced by mediators such as CagA (Brandt et al., 2005) and peptidoglycan (Viala et al., 2004) . The function of Caga (VirB11) has been shown to be necessary for IL-8 induction (Fischer et al., 2001) . Furthermore, systematic mutagenesis of the cag PAI revealed that the mechanism is independent of Cagb (VirD4), which is another TFSS protein that contains an NTP-binding motif. We tested Caga-ATPase inhibitor CHIR-1 for its effect on IL-8 secretion. It has been shown that IL-8 secretion of infected AGS cells is strongly enhanced after co-cultivation for 24-36 h (Brandt et al., 2005) . In particular, the potentiating effect of CagA on IL-8 production can be observed only after prolonged periods of co-cultivation (Brandt et al., 2005) . In our experiment, we quantified the amount of IL-8 release by AGS cells infected with CHIR-1-treated H. pylori G27 by ELISA after 24 h (Fig. 5) .
CHIR-1 reduces IL-8 secretion in infected AGS cells
IL-8 induction by H. pylori in epithelial cells is dependent on the presence of a functional TFSS
IL-8 production by infected AGS cells was found to be inhibited by CHIR-1 in a concentration-dependent manner (Fig. 5) . The effect varied with the amount of viable bacteria added (not shown), being most evident for a 1 : 10 dilution of the stock suspension. Interestingly, inhibition of IL-8 production was more pronounced after pre-incubation of infecting bacteria with CHIR-1. In the presence of 50 mM CHIR-1, the amount of secreted IL-8 dropped by 19?8 %. Using H. pylori cells that had been pre-incubated for 15 min with 50 mM CHIR-1, IL-8 secretion dropped by 36?6 %. In both cases, IL-8 concentrations were measured after 24 h co-cultivation, and the viability of the treated bacteria was tested by incubating an aliquot in BB medium at 37 u C for several days, under microaerophilic conditions. It was found that the CHIR-1 treatment did not impair viability of H. pylori under the conditions described (not shown). anti-phosphotyrosine IgGs, separation on a SDS-polyacrylamide gel, and blotting to a nitrocellulose membrane. Hence, only CagA protein that was phosphorylated after transfer to AGS cells (pCagA) is seen. Immunoprecipitated pCagA protein was detected using polyclonal anti-CagA serum and the ECL system. Lower panel, CagA protein was detected with polyclonal antiCagA serum, following electrophoresis of total cell extracts and blotting. Lanes: 1, AGS cells were co-cultivated with G27DcagY (virB10); 2 and 3, AGS cells were co-cultivated with G27 in the absence of the inhibitor; 4 and 5, AGS cells were cocultivated with G27 in the presence of 50 mM CHIR-1; 6 and 7, G27 cells were pre-incubated for 30 min in the presence of 50 mM CHIR-1. AGS cells were co-cultivated with the pretreated G27 in the presence of 50 mM CHIR-1. Fig. 4 . Kinetics of CagA translocation inhibition by CHIR-1. H. pylori cells were incubated for various periods of time in the presence of 50 mM CHIR-1. Following pre-incubation, bacteria were co-cultivated with AGS cells and 50 mM CHIR-1. Phosphorylated proteins were immunoprecipitated with antiphosphotyrosine antibodies, separated on a polyacrylamide gel, and blotted to a nitrocellulose membrane. pCagA protein (phosphorylated following transfer to AGS cells) was detected using a polyclonal anti-CagA antiserum, and quantified densitometrically. Relative amounts of pCagA are given in arbitrary units. Internal controls for quantification: total CagA protein and a-urease for H. pylori; a-tubulin for the AGS cells (not shown). Bars: 1, AGS cells were co-cultivated with H. pylori G27DcagA; 2, AGS cells were pre-incubated with CHIR-1 for 15 min (*) before co cultivation with G27; 3, AGS cells were co-cultivated with H. pylori G27; 4-9, H. pylori G27 was pre-incubated with CHIR-1 for the indicated periods of time, before co-cultivation with AGS cells (*). Grey bars, data points for the kinetic assays; white bars, control experiments. Quantifications were performed in triplicate. The results are means±SD.
CHIR-1 impairs gastric colonization of mice by H. pylori
To study the effect of the Caga inhibitor on early phase of colonization, we inoculated CD1 mice intragastrically with H. pylori strain SPM 326 that had been pre-treated with CHIR-1 (Marchetti et al., 1995) . SPM 326 is a mouseadapted type I strain, which responds to CHIR-1 in a way that is similar to G27 in various assays (data not shown). Mice were given roughly equal numbers of c.f.u. of nontreated and CHIR-1-treated bacteria. All animals tested survived treatment with bacteria plus Caga inhibitor at concentrations as high as 50 mM.
Infection/colonization was quantified by determining the number of bacteria in the stomach of each mouse after scraping gastric mucosa, and plating out serial dilutions. Increasing concentrations of CHIR-1 resulted in decreased colonization by H. pylori SPM 326, as measured by the number of c.f.u. recovered, in comparison with the c.f.u. recovered in the corresponding infected controls. When the stomachs of mice that received standard bacterial dose were analysed after sacrifice, 8 out of 10 mice were found to be H. pylori-positive in the infected control group, while a significantly lower number of H. pylori-positive mice (2 out of 10, P=0?011) were found infected in the group that concomitantly received 50 mM CHIR-1; the group that received 25 mM CHIR-1 showed a non-significant reduction in the number of infected mice (6 out of 10, P=0?31). In terms of bacterial colonization level, the group that received the standard bacterial dose showed a highly significant decrease in bacterial colonization (the geometric mean of c.f.u. per stomach was more than 2 log units lower than control group, P=0?0014) when concomitantly treated with 50 mM CHIR-1, and only a marginal reduction (P=0?139) when treated with 25 mM CHIR-1. The group that received the high bacterial dose showed a similar trend after 4 days of infection, although the differences with the control group were not significant: 9 out of 10 mice were found to be infected in the control group, 5 out of 10 (P=0?07) treated with 50 mM CHIR-1 were infected, and 8 out of 10 (P=0?5) treated with 25 mM CHIR-1 were infected; in quantitative terms, the reduction of infection almost reached a significant level (a geometric mean of more than 1 log unit lower than the control group, P=0?052) with 50 mM CHIR-1, and it was not significant (P=0?3) with 25 mM CHIR-1 (Fig. 6) .
DISCUSSION
Using the well-studied organism H. pylori as a model, we sought to find small molecules that inhibited the activity of the cag-encoded TFSS, which is an important factor in the pathogenicity of the bacterium (Bourzac & Guillemin, 2005; Censini et al., 1996) . A HTS involving 524 400 molecules identified 53 compounds that inhibited the TFSS-encoded ATPase Caga in vitro, with IC 50 values below 5 mM. Three selected compounds (CHIR-1, -2 and -3) had IC 50 values below 1 mM, and we considered these to be a reasonable starting point for identifying candidates as lead structures (Table 1) . The most potent substance, CHIR-1 (IC 50 0?45 mM), was chosen for further characterization.
The potential of CHIR-1 to block cag activity was assessed in several cell-based assays. We used CagA transfer and phosphorylation as early indicators of TFSS functionality, since phosphorylated CagA can be detected in AGS cells as early as 30 min after the start of co-cultivation (Selbach et al., 2003) . Furthermore, it has been verified recently that all translocated CagA is phosphorylated at tyrosine residues, before being processed in the Golgi apparatus (A. Covacci, F. Bagnoli & L. Buti, unpublished observations). IL-8 secretion was induced in AGS cells, as described in Methods, and the amount of secreted IL-8 was detected by ELISA. Bars: 1, AGS cells were co-cultivated with H. pylori G27; 2-4, co-cultivation was performed in the presence of 25, 50 and 75 mM CHIR-1, respectively; 5, G27* was preincubated for 15 min with 50 mM CHIR-1, and co-cultivation with AGS cells was in the presence of the same concentration of CHIR-1; 6, G27 in the absence of AGS cells or CHIR-1; 7, AGS cells in the absence of G27 or CHIR-1; 8, AGS cells in the presence of 50 mM CHIR-1. A square bracket joins data points obtained with and without pre-incubation of bacteria (PI) in the presence of 50 mM CHIR-1. IL-8 concentration in the culture supernatant was determined after 24 h co-cultivation. Quantifications were performed in triplicate. The results are means±SD.
In this work, we did not use caga (virB11) mutants as controls. Although this seems to be an obvious control to use, Caga mutants do not reflect the action of the inhibitor. TFSSs are multi-protein complexes consisting of a core of ten or more essential components. If any of these components is missing, the entire complex is absent from the cells. Caga is one of the essential components, and, consequently, using a Caga mutant as a control would not only eliminate the target for the inhibitor, but destroy the entire TFSS. Hence, one would neither see any transfer of CagA, nor see the phenotypic effects caused by either phosphorylated CagA or the mere presence of the TFSS. These effects are well studied, and described extensively in the literature (Christie et al., 2005; Fischer et al., 2001) . Exposing cells that bear a functional TFSS to an inhibitor such as CHIR-1 is a completely different situation. The effect is directed against the NTPase activity of VirB11, but the TFSS complex is present, and the effect is transitory. Nevertheless, in this situation, which is not comparable with that of a VirB11 mutant, we see that in the presence of CHIR-1, CagA transfer can be virtually abolished.
We demonstrated that CHIR-1 (i) inhibits CagA secretion into AGS cells, as shown by the marked reduction of intracellular CagA in AGS cells, and accumulation of CagA protein in bacterial cells when co-cultivated with AGS cells (Fig. 2) ; (ii) reduces the amount of phosphorylated CagA in infected AGS cells to the limits of detection (Fig. 3) ; and (iii) strongly reduces the number of cells showing the hummingbird phenotype, which is known to be a consequence of the presence of phosphorylated CagA in AGS cells (Fig. 1) .
We did not observe a reduction of viability in bacteria after several hours of incubation in the presence of 50 mM CHIR-1. In addition to general viability tests, the intracellular concentrations of two chosen proteins of H. pylori, CagA and a-urease, were found to be unaltered during a 4 h incubation period in the presence of 50 mM CHIR-1, when compared with an untreated control (Fig. 3 , and data not shown). Furthermore, there was no influence on AGS cell viability at CHIR-1 concentrations of up to 100 mM, when using the cell proliferation reagent WST-1.
A complete block of the TFSS-driven CagA translocation by inhibition of Caga ATPase activity was dependent on preincubation of the bacteria with CHIR-1 for a short period of time before allowing the bacteria to come into contact with the recipient cells (Figs 3 and 4) . Without a pre-incubation step, CagA translocation into AGS cells was not totally blocked, even in the presence of CHIR-1, and the hummingbird phenotype (Fig. 1 ) was observed. These findings indicate that the inhibitor interferes with a very early step in the TFSS mechanism, but not with the translocation step of the secretion process itself, or with other processes resulting in CagA-induced cellular changes.
In the common model of the TFSS machinery, it is generally assumed that VirB11-like proteins, such as Caga, are required for pilus assembly, functioning either as chaperones for pilus subunits or as a pump that drives pilus subunits across the inner membrane and assembles them into filamentous structures (Savvides et al., 2003; Sagulenko et al., 2001) . Interestingly, NTPases related to VirB11-type proteins are also found in type-4 pilus systems, in which they are supposed to be involved in active pilus extrusion and retraction (Planet et al., 2001) . Using electron microscopy to observe TFSSs during the initial phase of the transfer process, pilus structures have been seen to make the first contact between donor and recipient cells (Rohde et al., 2003) . Caga has also been found to be structurally similar to the p97 AAA ATPase, a protein involved in membrane fusion and organelle biogenesis (Atmakuri et al., 2004; Yeo & Waksman, 2004) . Therefore, one aspect of Caga activity A second dose of CHIR-1 was given 48 h p.i. Eleven and four days p.i., for low-and high-infection doses, respectively, groups were euthanized, and gastric mucosa was assessed for colonization by inoculating serial dilutions of mucosal cells on selective blood agar plates. Statistical analysis was performed using a MannWhitney U test. Symbols represent values for individual animals in a group, and horizontal bars represent geometric means. *, A significant reduction in c.f.u. compared with the non-treated control (P=0?0014).
might involve promoting intimate bacterial-host interactions, as a result of membrane fusion events or pilusmediated attachment.
Involvement of Caga during initial phase of contact might explain the requirement for a short period of pre-incubation of the bacteria with the inhibitor to inhibit CagA transfer completely (Figs 3-5) . Following formation of the initial contact, which is a very brief process of a few minutes only, there is evidence that a stable aggregate is formed involving tight contact between the host cells and the bacteria (Rohde et al., 2003) . At this point, it is conceivable that VirB11-related NTPase activity is no longer required, and that the subsequent secretion process is therefore resistant to any inhibitor of VirB11-type NTPases. In this context, it would be interesting to find out if the surface structures that have been identified recently in H. pylori (Tanaka et al., 2003; Rohde et al., 2003) are affected by CHIR-1.
IL-8 secretion, an important factor for chronic inflammation during H. pylori inflammation, has been found to be dependent on a functional cag PAI TFSS (Fischer et al., 2001) , and influenced by mediators, such as CagA (Brandt et al., 2005) and peptidoglycan (Viala et al., 2004) . Caga plays a crucial role in IL-8 induction, as shown in several mutagenesis studies (Fischer et al., 2001; Selbach et al., 2002) . Interestingly, besides individual strain characteristics influencing cytokine induction, IL-8 release has been found to be time dependent, and strongly enhanced at 24-36 h after infection (Brandt et al., 2005) . We investigated the influence of the Caga inhibitor on cytokine production in a cell culture model. After 24 h of co-cultivation at concentrations of CHIR-1 that reduced CagA translocation from pre-treated bacteria into AGS cells to detection limits (Fig. 3) , the secretion of IL-8 was also found to be significantly reduced (Fig. 5) . The effect was concentration dependent, and again it was enhanced by pre-incubation of infecting bacteria (Fig. 5) . Reduced IL-8 induction caused by missing translocated CagA is in accordance with published results (Brandt et al., 2005) that have identified CagA as a contributing factor for IL-8 induction.
Generally, in experiments in which CagA is missing, or does not contain EPIYA sites (Brandt et al., 2005) , or does not reach the recipient cells, higher IL-8 levels are observed than in respective studies involving deletion mutants of Caga. In the absence of Caga, IL-8 induction as low as 5-20 %, when compared with wild-type levels, has been observed (Selbach et al., 2002) . One reason for our observation of higher residual levels of IL-8 in the presence of CHIR-1 might be the substantial difference between the complete deletion of a gene and the inhibition of the enzymic activity of its product with a small molecule inhibitor. Regarding the multimeric composition of a TFSS, the deletion of a component results in more drastic changes, affecting also the overall structural integrity. In line with this, it has been found that other than TFSS-driven substrate transfer, overall structural intactness, and attachment of bacteria to epithelial cells, are crucial for cytokine production (Rieder et al., 1997) .
We studied the influence of CHIR-1 on bacterial colonization in a mouse model during the early stages of H. pylori infection. cag-PAI-positive type I strains are associated with increased virulence and severe clinical outcomes (Marchetti et al., 1995) . H. pylori type I strain SPM 326 was preincubated with different concentrations of CHIR-1 before infecting CD1 mice. After 11 days of infection with a standard bacterial dose, increasing concentrations of Caga inhibitor resulted in (i) decreased numbers of infected animals per group, and (ii) reduced numbers of recovered c.f.u. per stomach in infected mice (Fig. 6) . The reduced number of infected animals in the group pre-treated with 50 mM CHIR-1 was found to be significant when compared with the non-treated control. Whereas a trend in c.f.u. reduction was measured for the control group not treated with the inhibitor, and the group treated with 25 mM CHIR-1, almost no c.f.u. were recovered from mice infected with bacteria that had been pre-treated with 50 mM CHIR-1 (significant decrease of about 2 log units). Although not significant, a downward trend of infected animals and recovered c.f.u. with increasing amounts of CHIR-1 used to pre-treat bacteria was also found after 4 days of infection with the high bacterial dose. This suggests that CHIR-1 interferes with early events in H. pylori SPM 326 colonization of mouse gastric mucosa. In the literature, contradictory results can be found regarding whether or not cag PAI is essential for gastric colonization, and how it facilitates persistent infection; the results, apart from the specific phase of infection, depend highly on the bacterial and host phenotypes observed during in vivo study (Eaton et al., 2001; Marchetti & Rappuoli, 2002) . Results reported by Eaton et al. (2001) indicate that deletion of cag PAI in H. pylori strain SS1 is not essential for colonization. However, during the very early phase of infection [2 days post-infection (p.i.)], a cag-negative strain of H. pylori 26695 tended to colonize piglets to a lesser extent than the respective wildtype strain (Eaton et al., 2001) . Studies using the wellestablished Mongolian gerbil model suggest that intact TFSS of H. pylori has a role in colonization of the gastric corpus (Rieder et al., 2005) . It has been suggested that cag PAI might be important for a specific step in colonization (Monack et al., 2004) . Our results are in line with the work performed by Marchetti and Rappuoli (2002) , in which, during the early phase of infection, colonization efficiency in CD1 mice was reduced by 200-fold for a Caga mutant of H. pylori strain SS1; inactivation of cag genes essential for TFSS function also led to a reduced number of infected animals (mean infection rate was 20-40 % when compared with animals infected with the wild-type). Inactivation of Caga, and the resulting loss of TFSS functionality, suggest a reduced bacterial virulence for type I strains of H. pylori in animal models.
Our initial studies on CHIR-1 activity in vivo encourage further investigations using different systems, such as the Mongolian gerbil model, to gain a deeper understanding of the properties of CHIR-1 in vivo. At this point, we cannot exclude the fact that additional effects of CHIR-1 may contribute to the measured reduction of colonization during early stages of infection. These effects include interaction with other VirB11-like proteins in H. pylori, such as the VirB11-homologue located within the flagellar export locus (Porwollik et al., 1999) , which has been found to be essential for gastric colonization in a Mongolian gerbil model of infection (Kavermann et al., 2003) .
For TFSS Cagb, which is another protein containing NTPbinding motifs, the effect of CHIR-1 could not be tested, since we did not succeed in demonstrating the NTPase activity in vitro. However, the primary sequences, including the NTP-binding motifs of Caga and b, differ markedly from each other; therefore, it is very unlikely that a molecule selected for its activity on Caga would also interact with Cagb.
Our study formally demonstrates that it is possible to identify inhibitors of virulence-related TFSSs, as shown in our model of study H. pylori. Nevertheless, many additional questions need to be addressed before an enzymic inhibitor can be transformed into an efficient antibiotic. Studies on the suitability of a compound for use as a drug (e.g. solubility and uptake), and its toxicity and pharmacokinetics, together with further optimization of lead compounds, must be performed in order to obtain the desired properties.
Presently, we are studying the interaction between Caga and CHIR-1 using co-crystallization and molecular modelling techniques. Detailed structural information might allow rational modifications of the lead structure of the inhibitor to further improve its efficacy. The crystal structure of Caga has been solved by Yeo et al. (2000) . In addition, the synthesis of radioactively labelled CHIR-1 might be helpful for a detailed investigation of the uptake, and further interaction of the inhibitor with Caga, in the cellular system.
To our knowledge, this is the first report that describes a specific inhibitor of a TFSS that is capable of interfering with an essential enzymic function of the injectosome. The compound efficiently inhibited the function of a single component of the H. pylori cag TFSS, Caga, and thereby blocked the biological activity of the system as a whole. Initial in vivo evaluation studies indicated that CHIR-1 mediated the reduction of pathogenic effects of H. pylori in mice. Recently, for several conjugative systems, inhibition by unsaturated fatty acids was demonstrated, although the mechanism of action of these compounds remains to be elucidated (Fernandez-Lopez et al., 2005) . Others have shown that type III secretion systems are also potential targets for new antimicrobials (Nordfelth et al., 2005; Kauppi et al., 2003) . Our ongoing work will extend these studies to other pathogens in which TFSSs are required virulence factors. Future experiments could give more information on the specificity of the inhibitors identified using H. pylori Caga that, in principle, might also be active on similar NTPases from other pathogens that carry a TFSS.
